/주식/PHVS
PHVS

PHVS

USD

Pharvaris N.V. Ordinary Shares

$21.640-0.842 (-3.746%)

실시간 가격

Healthcare
생명공학
스위스

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$22.482

고가

$22.482

저가

$21.585

거래량

0.14M

기업 기본 정보

시가총액

1.4B

산업

생명공학

국가

Switzerland

거래 통계

평균 거래량

0.19M

거래소

NMS

통화

USD

52주 범위

저가 $11.51현재가 $21.640고가 $26.33

관련 뉴스

GlobeNewswire

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living

더 보기
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Analyst Upgrades

HC Wainwright & Co. Initiates Coverage On Pharvaris with Buy Rating, Announces Price Target of $60

HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Pharvaris with a Buy rating and announces Price Target of $60.

더 보기
HC Wainwright & Co. Initiates Coverage On Pharvaris with Buy Rating, Announces Price Target of $60
Analyst Upgrades

B of A Securities Upgrades Pharvaris to Neutral, Raises Price Target to $27

B of A Securities analyst Tazeen Ahmad upgrades Pharvaris from Underperform to Neutral and raises the price target from $16 to $27.

더 보기
B of A Securities Upgrades Pharvaris to Neutral, Raises Price Target to $27